Prelude Capital Management, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Prelude Capital Management, LLC
- $1.39 Billion
- Q2 2024
A detailed history of Prelude Capital Management, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 22,850 shares of CPRX stock, worth $454,258. This represents 0.03% of its overall portfolio holdings.
Number of Shares
22,850
Previous 25,899
11.77%
Holding current value
$454,258
Previous $412,000
14.32%
% of portfolio
0.03%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$372 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$181 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$161 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$120 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$59.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.04B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...